GI Innovation begins prostate cancer trial with J&J drug

South Korean biotech firm GI Innovation has administered the first dose in a global clinical trial combining its experimental immunotherapy GI-102 with Johnson & Johnson's prostate cancer drug candidate pasritamig, marking a new step in its efforts to develop treatments for advanced cancer. The company said Thursday…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.